Literature DB >> 19841380

Family history of melanoma and Parkinson disease risk.

X Gao1, K C Simon, J Han, M A Schwarzschild, A Ascherio.   

Abstract

BACKGROUND: Co-occurrence of Parkinson disease (PD) and melanoma has been reported in numerous studies. If this was due to common genetic mechanisms, a positive family history of melanoma would be associated with an excessive PD risk, independent of environmental risk factors for PD.
METHODS: We prospectively examined associations between a family history of melanoma and PD among 157,036 men and women free of PD at baseline (1990 for men and 1982 for women) who participated in 2 ongoing US cohorts: the Health Professional Follow-up Study and the Nurses' Health Study. Information on family history of melanoma in parents or siblings was assessed via questionnaire. Relative risks and 95% confidence intervals were estimated using Cox proportional hazards models and pooled using a fixed-effects model.
RESULTS: During 14-20 years follow-up, we identified 616 incident PD cases. A family history of melanoma in a first-degree relative was associated with a higher risk of PD (multivariate relative risk = 1.85; 95% confidence interval: 1.2, 2.8; p = 0.004), after adjusting for smoking, ethnicity, caffeine intake, and other covariates. In contrast, we did not observe significant associations between a family history of colorectal, lung, prostate, or breast cancer and PD risk. Interactions between melanoma family history and age, smoking, or caffeine intake were not significant and subgroup analyses according to these factors generated similar results.
CONCLUSIONS: Our findings support the notion that melanoma and Parkinson disease (PD) share common genetic components. The genetic determinants of melanoma could therefore be explored as susceptibility candidate genes for PD.

Entities:  

Mesh:

Year:  2009        PMID: 19841380      PMCID: PMC2764417          DOI: 10.1212/WNL.0b013e3181bd13a1

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  33 in total

1.  Inhibition of CDKs: a strategy for preventing kainic acid-induced apoptosis in neurons.

Authors:  E Verdaguer; Elvira G Jordà; Alessandra Stranges; Anna M Canudas; Andrés Jiménez; Francesc X Sureda; Mercè Pallas; Antoni Camins
Journal:  Ann N Y Acad Sci       Date:  2003-12       Impact factor: 5.691

2.  Multiple primary melanoma following administration of levodopa.

Authors:  J L Skibba; J Pinckley; E F Gilbert; R O Johnson
Journal:  Arch Pathol       Date:  1972-06

3.  Prospective study of caffeine consumption and risk of Parkinson's disease in men and women.

Authors:  A Ascherio; S M Zhang; M A Hernán; I Kawachi; G A Colditz; F E Speizer; W C Willett
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

Review 4.  Levodopa therapy and the risk of malignant melanoma.

Authors:  J F Siple; D C Schneider; W A Wanlass; B K Rosenblatt
Journal:  Ann Pharmacother       Date:  2000-03       Impact factor: 3.154

5.  Risk of melanoma in relation to smoking, alcohol intake, and other factors in a large occupational cohort.

Authors:  D Michal Freedman; Alice Sigurdson; Michele Morin Doody; R Sowmya Rao; Martha S Linet
Journal:  Cancer Causes Control       Date:  2003-11       Impact factor: 2.506

Review 6.  Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history.

Authors:  Harvey J Murff; David R Spigel; Sapna Syngal
Journal:  JAMA       Date:  2004-09-22       Impact factor: 56.272

Review 7.  Malignant melanoma and levodopa in Parkinson's disease: causality or coincidence?

Authors:  Katherine H Fiala; Jacqueline Whetteckey; Bala V Manyam
Journal:  Parkinsonism Relat Disord       Date:  2003-08       Impact factor: 4.891

8.  Food-based validation of a dietary questionnaire: the effects of week-to-week variation in food consumption.

Authors:  S Salvini; D J Hunter; L Sampson; M J Stampfer; G A Colditz; B Rosner; W C Willett
Journal:  Int J Epidemiol       Date:  1989-12       Impact factor: 7.196

9.  Pigmentation genes link Parkinson's disease to melanoma, opening a window on both etiologies.

Authors:  Elena Herrero Hernández
Journal:  Med Hypotheses       Date:  2008-11-21       Impact factor: 1.538

10.  Atypical cancer pattern in patients with Parkinson's disease.

Authors:  J H Olsen; S Friis; K Frederiksen; J K McLaughlin; L Mellemkjaer; H Møller
Journal:  Br J Cancer       Date:  2005-01-17       Impact factor: 7.640

View more
  45 in total

1.  Nasu-Hakola disease and primary microglial dysfunction.

Authors:  Marino M Bianchin; Kelin C Martin; Ana C de Souza; Marina A de Oliveira; Carlos R de Mello Rieder
Journal:  Nat Rev Neurol       Date:  2010-09       Impact factor: 42.937

2.  Malignant melanoma, breast cancer and other cancers in patients with Parkinson's disease.

Authors:  Kathrine Rugbjerg; Søren Friis; Christina Funch Lassen; Beate Ritz; Jørgen H Olsen
Journal:  Int J Cancer       Date:  2012-03-22       Impact factor: 7.396

3.  Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls.

Authors:  Ilir Agalliu; Roberto A Ortega; Marta San Luciano; Anat Mirelman; Claustre Pont-Sunyer; Kathrin Brockmann; Dolores Vilas; Eduardo Tolosa; Daniela Berg; Bjørg Warø; Amanda Glickman; Deborah Raymond; Rivka Inzelberg; Javier Ruiz-Martinez; Elisabet Mondragon; Eitan Friedman; Sharon Hassin-Baer; Roy N Alcalay; Helen Mejia-Santana; Jan Aasly; Tatiana Foroud; Karen Marder; Nir Giladi; Susan Bressman; Rachel Saunders-Pullman
Journal:  Mov Disord       Date:  2019-07-26       Impact factor: 10.338

4.  The melanoma-linked "redhead" MC1R influences dopaminergic neuron survival.

Authors:  Xiqun Chen; Hongxiang Chen; Waijiao Cai; Michael Maguire; Bailiu Ya; Fuxing Zuo; Robert Logan; Hui Li; Katey Robinson; Charles R Vanderburg; Yang Yu; Yinsheng Wang; David E Fisher; Michael A Schwarzschild
Journal:  Ann Neurol       Date:  2017-01-23       Impact factor: 10.422

5.  Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis.

Authors:  Ilir Agalliu; Marta San Luciano; Anat Mirelman; Nir Giladi; Bjorg Waro; Jan Aasly; Rivka Inzelberg; Sharon Hassin-Baer; Eitan Friedman; Javier Ruiz-Martinez; Jose Felix Marti-Masso; Avi Orr-Urtreger; Susan Bressman; Rachel Saunders-Pullman
Journal:  JAMA Neurol       Date:  2015-01       Impact factor: 18.302

6.  LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson disease.

Authors:  Rachel Saunders-Pullman; Matthew J Barrett; Kaili M Stanley; Marta San Luciano; Vicki Shanker; Lawrence Severt; Ann Hunt; Deborah Raymond; Laurie J Ozelius; Susan B Bressman
Journal:  Mov Disord       Date:  2010-11-15       Impact factor: 10.338

Review 7.  Meta-analysis of the relationship between Parkinson disease and melanoma.

Authors:  Rui Liu; Xiang Gao; Yi Lu; Honglei Chen
Journal:  Neurology       Date:  2011-06-07       Impact factor: 9.910

8.  Parkinson's disease-related protein, alpha-synuclein, in malignant melanoma.

Authors:  Yasuhiro Matsuo; Tetsu Kamitani
Journal:  PLoS One       Date:  2010-05-05       Impact factor: 3.240

9.  The role of the melanoma gene MC1R in Parkinson disease and REM sleep behavior disorder.

Authors:  Ziv Gan-Or; Noreen Mohsin; Simon L Girard; Jacques Y Montplaisir; Amirthagowri Ambalavanan; Stephanie Strong; Victoria Mallett; Sandra B Laurent; Cynthia V Bourassa; Michel Boivin; Melanie Langlois; Isabelle Arnulf; Birgit Högl; Birgit Frauscher; Christelle Monaca; Alex Desautels; Jean-François Gagnon; Ronald B Postuma; Patrick A Dion; Yves Dauvilliers; Nicolas Dupre; Roy N Alcalay; Guy A Rouleau
Journal:  Neurobiol Aging       Date:  2016-04-06       Impact factor: 4.673

10.  Role of Ser129 phosphorylation of α-synuclein in melanoma cells.

Authors:  Byung Rho Lee; Yasuhiro Matsuo; Anil G Cashikar; Tetsu Kamitani
Journal:  J Cell Sci       Date:  2012-11-30       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.